Comparative Pharmacology
Head-to-head clinical analysis: SOLIFENACIN SUCCINATE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLIFENACIN SUCCINATE versus VESICARE LS.
SOLIFENACIN SUCCINATE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic